Grant of Interim Extension of the Term of U.S. Patent No. 4,591,585; Atamestane, 32760-32761 [05-11175]

Download as PDF 32760 Federal Register / Vol. 70, No. 107 / Monday, June 6, 2005 / Notices We are issuing and publishing these results in accordance with sections 751(a)(1) and 777(i)(1) of the Act. Dated: May 31, 2005. Susan H. Kuhbach, Acting Assistant Secretary for Import Administration. [FR Doc. E5–2877 Filed 6–3–05; 8:45 am] BILLING CODE 3510–DS–S DEPARTMENT OF COMMERCE National Oceanic and Atmospheric Administration [I.D. 053105E] New England Fishery Management Council; Public Meeting National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce. ACTION: Notice of a public meeting. AGENCY: SUMMARY: The New England Fishery Management Council (Council) will hold a three-day Council meeting on June 21–23, 2005, to consider actions affecting New England fisheries in the exclusive economic zone (EEZ). DATES: The meeting will be held on Tuesday, Wednesday and Thursday, June 21–23, 2005 beginning at 8 a.m. each day. ADDRESSES: The meeting will be held at the Eastland Park Hotel, 157 High Street, Portland, ME 04101; telephone: (207) 775–5411. Council address: to the New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950. FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council; (978) 465–0492. SUPPLEMENTARY INFORMATION: Tuesday, June 21, 2005 Following introductions, the Council will receive reports from the Council Chairman and Executive Director, the NMFS Regional Administrator, Northeast Fisheries Science Center and Mid-Atlantic Fishery Management Council liaisons, NOAA General Counsel and representatives of the U.S. Coast Guard, NMFS Enforcement and the Atlantic States Marine Fisheries Commission. There also will be an update on the New England Fleet Visioning Project. During the morning session, the Council will receive a briefing on a series of advisory panel meetings concerning development of an New England Fishery Management Council (NEFMC) Conservation and VerDate jul<14>2003 14:25 Jun 03, 2005 Jkt 205001 Management Policy. The policy, which the Council will consider and could approve, concerns issues related to capacity, use of input/output controls and resource allocation issues. The Magnuson-Stevens Act Reauthorization Committee will provide recommendations for Council approval concerning positions on changes to the Act. The rest of the day will be spent on proposed Amendment 1 to the Herring Fishery Management Plan (FMP). Members will review and consider management alternatives to be included in the associated Draft Supplemental Environmental Impact Statement, select preferred alternatives, and approve the document for public hearings. Wednesday, June 22, 2005 During the Wednesday morning session, the Council will review issues identified at recent port meetings and related to fishery regulations and safety at sea. Follow up actions may be recommended. An open public comment period will be available for items not listed on the agenda, followed by a report from the chairman of the Transboundary Management Guidance Committee. That report will include a review of discussions about an alternative to the current harvest strategy for haddock. There also will be a report from the Scientific and Statistical Committee about an alternative model to assess groundfish stocks. The Council will then take initial action on Framework Adjustment 42 to the Northeast Multispecies FMP by formally identifying what measures will be analyzed and further considered in the adjustment. NOAA Fisheries scientists will report to the Council on invasive colonial tunicates now found on Georges Bank. At the end of the day final action on proposed Framework Adjustment 1 to the Spiny Dogfish FMP will be considered. Measures will address a modification to the plan that would allow multi-year specifications to be set for the fishery. At the end of the day the Council will discuss and possibly approve a motion to give sole management authority for spiny dogfish to the Mid-Atlantic Council and assume sole management authority for monkfish. Thursday, June 23, 2005 The morning session will begin with a report from the Council’s Research Steering Committee concerning their review of several cooperative research project final reports. There will be summary of the most recent activities currently underway and associated with development of essential fish habitat (EFH) Omnibus Amendment 2 as well PO 00000 Frm 00018 Fmt 4703 Sfmt 4703 as a review of the outcome of the NEFMC’s Marine Protected Areas Education and Outreach Workshops. The last item on the agenda will address Framework Adjustment 18 to the Sea Scallop Fishery Management Plan. This will include a report on 2005 assessment updates and forecasts. There will be consideration of a recommendation for emergency action to end possible overfishing of the scallop resource and approval of comments on proposed sea turtle conservation measures. Although other non-emergency issues not contained in this agenda may come before this Council for discussion, those issues may not be the subjects of formal action during this meeting. Council action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the MagnusonStevens Act, provided that the public has been notified of the Council’s intent to take final action to address the emergency. Special Accommodations This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Paul J. Howard (see ADDRESSES) at least 5 days prior to the meeting date. Dated: May 31, 2005. Emily Menashes, Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service [FR Doc. E5–2865 Filed 6–3–05; 8:45 am] BILLING CODE 3510–22–S DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. 2005–P–063] Grant of Interim Extension of the Term of U.S. Patent No. 4,591,585; Atamestane United States Patent and Trademark Office. ACTION: Notice of interim patent term extension. AGENCY: SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a second one-year interim extension of the term of U.S. Patent No. 4,591,585. FOR FURTHER INFORMATION CONTACT: Karin Ferriter by telephone at (571) 272–7744; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop E:\FR\FM\06JNN1.SGM 06JNN1 Federal Register / Vol. 70, No. 107 / Monday, June 6, 2005 / Notices Patent Ext., P.O. Box 1450, Alexandria, VA 22313–1450; by fax marked to her attention at (571) 273–7744; or by e-mail to Karin.Ferriter@uspto.gov. Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On May 4, 2005, Intarcia Therapeutics, Inc., on behalf of patent owner Schering Aktiengesellschaft, timely filed an application under 35 U.S.C. 156(d)(5) for a second interim extension of the term of U.S. Patent No. 4,591,585. The patent claims the product atamestane. The application indicates that a New Drug Application for the human drug product atamestane has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for an additional period of one year as required by 35 U.S.C. 156(d)(5)(C). Since it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (June 18, 2005), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,591,585 is granted for a period of one year from the expiration date of the patent, i.e., until June 18, 2006. SUPPLEMENTARY INFORMATION: Dated: May 26, 2005. Jon W. Dudas, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. 05–11175 Filed 6–3–05; 8:45 am] BILLING CODE 3510–16–P VerDate jul<14>2003 14:25 Jun 03, 2005 Jkt 205001 DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. 2005–P–064] Grant of Interim Extension of the Term of U.S. Patent No. 4,567,264; Ranolazine United States Patent and Trademark Office. ACTION: Notice of interim patent term extension. AGENCY: SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a third one-year interim extension of the term of U.S. Patent No. 4,567,264. FOR FURTHER INFORMATION CONTACT: Karin Ferriter by telephone at (571)272– 7744; by mail marked to her attention and addressed to Mail Stop Patent Ext., Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313–1450; by fax marked to her attention at (571)273– 7744; or by e-mail to Karin.Ferriter@uspto.gov. Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On March 25, 2005, patent owner Roche Palo Alto LLC, timely filed an application under 35 U.S.C. 156(d)(5) for a third interim extension of the term of U.S. Patent No. 4,567,264. The patent claims the active ingredient ranolazine (RanexaTM). The application indicates, and the Food and Drug Administration (FDA) has confirmed, that a New Drug Application for the human drug product ranolazine has been filed and is currently undergoing regulatory review before the FDA for permission to market or use the product commercially. Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for an additional period of one year as required by 35 U.S.C. 156(d)(5)(C). Since it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (May 18, 2005), the term of the patent will be SUPPLEMENTARY INFORMATION: PO 00000 Frm 00019 Fmt 4703 Sfmt 4703 32761 extended under 35 U.S.C. 156(d)(5) for an additional year. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,567,264 is granted for an additional period of one year from the extended expiration date of the patent, i.e., until May 18, 2006. Dated: May 26, 2005. Jon W. Dudas, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. 05–11176 Filed 6–3–05; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No.: 2003–P–018] Notice of Availability of and Request for Comments on Green Paper Concerning Restriction Practice United States Patent and Trademark Office, Commerce. ACTION: Request for comments. AGENCY: SUMMARY: The United States Patent and Trademark Office (USPTO) has established a 21st Century Strategic Plan to transform the USPTO into a quality focused, highly productive, responsive organization supporting a market-driven intellectual property system. As a part of this plan, the USPTO is conducting a study of its restriction practice. As part of this study, the Office requested public comments to help guide the study. After careful consideration of the public comments and an internal review, the USPTO has prepared a ‘‘Green Paper’’ describing and evaluating four options to reform restriction practice suggested by various members of the public. Prior to considering the desirability of drafting proposed legislation in a ‘‘White Paper’’ on reforming restriction practice, the USPTO is seeking public comment on the Green Paper. DATES: Comment Deadline Date: To be ensured of consideration, written comments must be received on or before August 5, 2005. No public hearing will be held. ADDRESSES: Comments should be sent by electronic mail message over the Internet addressed to: unity.comments@uspto.gov. Comments may also be submitted by mail addressed to: Mail Stop Comments— Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313–1450, or by facsimile to (571) 273–7735, marked to the attention of Robert A. E:\FR\FM\06JNN1.SGM 06JNN1

Agencies

[Federal Register Volume 70, Number 107 (Monday, June 6, 2005)]
[Notices]
[Pages 32760-32761]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-11175]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. 2005-P-063]


Grant of Interim Extension of the Term of U.S. Patent No. 
4,591,585; Atamestane

AGENCY: United States Patent and Trademark Office.

ACTION: Notice of interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued a 
certificate under 35 U.S.C. 156(d)(5) for a second one-year interim 
extension of the term of U.S. Patent No. 4,591,585.

FOR FURTHER INFORMATION CONTACT: Karin Ferriter by telephone at (571) 
272-7744; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop

[[Page 32761]]

Patent Ext., P.O. Box 1450, Alexandria, VA 22313-1450; by fax marked to 
her attention at (571) 273-7744; or by e-mail to 
Karin.Ferriter@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to a year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On May 4, 2005, Intarcia Therapeutics, Inc., on behalf of patent 
owner Schering Aktiengesellschaft, timely filed an application under 35 
U.S.C. 156(d)(5) for a second interim extension of the term of U.S. 
Patent No. 4,591,585. The patent claims the product atamestane. The 
application indicates that a New Drug Application for the human drug 
product atamestane has been filed and is currently undergoing 
regulatory review before the Food and Drug Administration for 
permission to market or use the product commercially.
    Review of the application indicates that except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for an additional period of one year 
as required by 35 U.S.C. 156(d)(5)(C). Since it is apparent that the 
regulatory review period will continue beyond the extended expiration 
date of the patent (June 18, 2005), interim extension of the patent 
term under 35 U.S.C. 156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 4,591,585 is granted for a period of one year from the 
expiration date of the patent, i.e., until June 18, 2006.

    Dated: May 26, 2005.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of 
the United States Patent and Trademark Office.
[FR Doc. 05-11175 Filed 6-3-05; 8:45 am]
BILLING CODE 3510-16-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.